Andra AP-fonden’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.7M | Buy |
86,697
+38,157
| +79% | +$13M | 0.34% | 52 |
|
|
2025
Q4 | $19.3M | Buy |
48,540
+27,840
| +134% | +$12.3M | 0.24% | 125 |
|
|
2025
Q3 | $9.44M | Buy |
20,700
+13,800
| +200% | +$5.62M | 0.12% | 217 |
|
|
2025
Q2 | $2.25M | Sell |
6,900
-9,900
| -59% | -$2.74M | 0.03% | 340 |
|
|
2025
Q1 | $4.54M | Sell |
16,800
-11,100
| -40% | -$2.85M | 0.07% | 293 |
|
|
2024
Q4 | $6.57M | Buy |
27,900
+15,200
| +120% | +$4M | 0.11% | 265 |
|
|
2024
Q3 | $3.49M | Buy |
12,700
+9,600
| +310% | +$2.5M | 0.05% | 333 |
|
|
2024
Q2 | $753K | Buy |
+3,100
| New | +$489K | 0.01% | 377 |
|
|
2024
Q1 | – | Sell |
-35,500
| Closed | -$6.8M | – | 368 |
|
|
2023
Q4 | $6.8M | Buy |
35,500
+1,000
| +3% | +$170K | 0.36% | 132 |
|
|
2023
Q3 | $6.11M | Sell |
34,500
-6,000
| -15% | -$1.14M | 0.36% | 127 |
|
|
2023
Q2 | $7.69M | Sell |
40,500
-4,700
| -10% | -$932K | 0.19% | 214 |
|
|
2023
Q1 | $9.05M | Sell |
45,200
-10,400
| -19% | -$2.19M | 0.24% | 147 |
|
|
2022
Q4 | $13.2M | Buy |
55,600
+7,000
| +14% | +$1.49M | 0.4% | 19 |
|
|
2022
Q3 | $9.73M | Buy |
48,600
+6,500
| +15% | +$1.24M | 0.32% | 58 |
|
|
2022
Q2 | $6.14M | Buy |
+42,100
| New | +$5.97M | 0.18% | 256 |
|
|
2021
Q4 | $4.82M | Buy |
28,400
+8,500
| +43% | +$1.58M | 0.1% | 419 |
|
|
2021
Q3 | $3.76M | Buy |
19,900
+2,500
| +14% | +$469K | 0.08% | 488 |
|
|
2021
Q2 | $2.95M | Buy |
17,400
+1,400
| +9% | +$205K | 0.06% | 532 |
|
|
2021
Q1 | $2.26M | Sell |
16,000
-2,500
| -14% | -$376K | 0.05% | 537 |
|
|
2020
Q4 | $2.4M | Buy |
18,500
+4,300
| +30% | +$574K | 0.05% | 552 |
|
|
2020
Q3 | $2.07M | Sell |
14,200
-23,900
| -63% | -$3.4M | 0.06% | 562 |
|
|
2020
Q2 | $5.64M | Buy |
38,100
+3,700
| +11% | +$499K | 0.16% | 280 |
|
|
2020
Q1 | $3.74M | Buy |
34,400
+20,000
| +139% | +$2.31M | 0.14% | 388 |
|
|
2019
Q4 | $1.66M | Buy |
14,400
+11,600
| +414% | +$1.16M | 0.05% | 626 |
|
|
2019
Q3 | $225K | Buy |
+2,800
| New | +$222K | 0.01% | 657 |
|
|
2019
Q2 | – | Sell |
-5,600
| Closed | -$523K | – | 658 |
|
|
2019
Q1 | $523K | Buy |
+5,600
| New | +$468K | 0.02% | 635 |
|
|
2018
Q3 | – | Sell |
-12,800
| Closed | -$1.26M | – | 637 |
|
|
2018
Q2 | $1.26M | Sell |
12,800
-1,900
| -13% | -$188K | 0.03% | 623 |
|
|
2018
Q1 | $1.75M | Buy |
14,700
+12,800
| +674% | +$1.65M | 0.05% | 622 |
|
|
2017
Q4 | $241K | Buy |
+1,900
| New | +$239K | 0.01% | 672 |
|
Other funds holding ALNY
Andra AP-fonden's ALNY Position: Q1 2026 in Review
Andra AP-fonden increased its Alnylam Pharmaceuticals (ALNY) stake by 79% in Q1 2026, buying an estimated $13M and bringing the position to 86,697 shares worth $28.7M. The position accounts for 0.34% of the portfolio, ranked #52.
Andra AP-fonden first reported a position in ALNY in Q4 2017 and has held it in 29 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Andra AP-fonden held 86,697 shares of Alnylam Pharmaceuticals worth $28.7M as of Q1 2026.
- Andra AP-fonden bought 38,157 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $13M.
- Alnylam Pharmaceuticals made up 0.34% of Andra AP-fonden's portfolio in Q1 2026, its #52 holding.
- Andra AP-fonden first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 29 quarters since.
- 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Andra AP-fonden's 13F filing for Q1 2026, filed 8 May 2026.